7B7: a novel antibody directed against the Ku70/Ku80

heterodimer blocks invasion in pancreatic and lung cancer cells by O'Sullivan, Dermot et al.
RESEARCH ARTICLE
7B7: a novel antibody directed against the Ku70/Ku80
heterodimer blocks invasion in pancreatic and lung cancer cells
Dermot O’Sullivan & Michael Henry & Helena Joyce & Naomi Walsh &
Edel Mc Auley & Paul Dowling & Niall Swan & Michael Moriarty &
Paul Barnham & Martin Clynes & Annemarie Larkin
Received: 28 January 2014 /Accepted: 17 March 2014 /Published online: 18 April 2014
# International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract Development of more effective therapeutic strate-
gies for cancers of high unmet need requires the continued
discovery of disease-specific protein targets for therapeutic
antibody targeting. In order to identify novel proteins associ-
ated with cancer cell invasion/metastasis, we present here an
alternative to antibody targeting of cell surface proteins with
an established role in invasion; our functional antibody
screening approach involves the isolation and selection of
MAbs that are primarily screened for their ability to inhibit
tumour invasion. A clonal population of the Mia PaCa-2, a
pancreatic ductal adenocarcinoma (PDAC) cell line, which
displays a highly invasive phenotype, was used to generate
MAbs with the objective of identifying membrane targets
directly involved in cancer invasion. Selected MAb 7B7 can
significantly reduce invasion in a dose-responsive manner in
Mia PaCa-2 clone 3 and DLKP-M squamous lung carcinoma
cells. Using immunoprecipitation and liquid chromatography-
tandem mass spectrometry (LC-MS-MS) analysis, the target
antigen of anti-invasive antibody, 7B7, was determined to be
the heterodimeric Ku antigen, Ku70/80, a core protein com-
posed of the Ku70 and Ku80 subunits which is involved in
non-homologous end-joining (NHEJ) DNA repair. RNA
interference-mediated knockdown of Ku70 and Ku80 resulted
in a marked decrease in the invasive capacity of Mia PaCa-2
clone 3 and DLKP-M cells, indicating that Ku70/Ku80 is
functionally involved in pancreatic and lung cancer invasion.
Immunohistochemical analysis demonstrated Ku70/Ku80 im-
munoreactivity in 37 PDAC tumours, indicating that this
heterodimer is highly expressed in this aggressive cancer type.
This study demonstrates that a functional MAb screening
approach coupled with immunoprecipitation/proteomic anal-
yses can be successfully applied to identify functional anti-
invasive MAbs and potential novel targets for therapeutic
antibody targeting.
Keywords Monoclonal antibody .Cancermetastasis .Cancer
invasion . Ku70/Ku80 . Target discovery
Introduction
Metastasis remains the major driver of mortality in patients
with cancer, and, in contrast to primary cancer, metastasis is a
major therapeutic challenge; currently, there are no effective
treatments for the vast majority of metastatic cancers. Only a
very small number of therapeutic targets have been
investigated/evaluated clinically for their ability to limit
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metastasis—none of these are in clinical use [1, 2]. Identification
of targets with a role in cancer invasion/metastasis may have the
potential to be developed as novel treatment strategies to treat (or
delay) metastasis. Monoclonal-antibody-based treatment of can-
cer has, in the last two decades, become established as one of the
most successful therapeutic strategies for treating patients with
haematological and solid tumours [3]. Antibody cancer thera-
peutics are highly specific and potent drugs, which exert their
therapeutic effect through modulation of key signalling path-
ways to reduce cell growth or induce apoptosis and/or triggering
of antibody-unique effect or functions. There are now 14
antibody-based products approved to treat cancer patients in
the European Union (EU) and the USA [4, 5]. Therapeutic
cancer antibodies are, however, focused on a relatively narrow
set of targets; one third of all antibodies (approved and in
development) are specific for just five targets [5, 6]. Currently,
the key challenge in new antibody cancer therapeutics is the
continued discovery of novel targets that are associated with
hallmarks of cancer pathophysiology such as metastatic poten-
tial and drug sensitivity that are suitable for antibody-based
targeting. The ideal tumour target antigen will be easily acces-
sible from the tumour neovasculature and shows abundant
tumour expression with limited normal tissue expression.
First generation antibodies such as trastuzumab and rituximab
show significant clinical benefits and have revolutionised treat-
ment of human epidermal growth factor receptor 2 (HER-2)
positive breast cancer and CD-20 positive lymphomas.
However, conventional unmodified antibodies have limitations
such as low tumour to blood ratio due to long serum half-life,
limited tissue penetration and specificity for a single epitope, and
they can sometimes be limited in efficacy [4]. There has been a
drive to improve established targeted therapeutic antibodies using
glycoengineering approaches to increase potency (e.g. develop-
ment of non-fucosylated antibodies) and the use of antibody
fragments for better tissue penetration.Development of bispecific
antibodies (bsABs) (e.g. catumaxomab) and trifunctional anti-
bodies is a big growth area; these antibodies can bind to two
different tumour antigens or to a tumour antigen and an antigen
in the tumour stroma/microenvironment such as an immune
killer cell [7, 8]. Antibody-drug conjugates (ADCs) such as the
recently approved trastuzumab-DM1 aim to overcome the limi-
tations of non-specific cytotoxics and ineffective MAb therapy,
through the use of a highly potent cytotoxic agent (payload)
which is directed to the tumour by appending it to an antibody
or antibody fragment. ADCs currently account for around 15 %
of the clinical stage anticancer-antibody-based pipeline
outnumbering bispecific antibodies and antibody fragments [9].
Currently, the key challenge for ADC cancer therapeutics is the
ongoing identification of tractable targets [10].
Large numbers of potential cancer-associated antigens
have been identified in a number of different cancer types
using various high-throughput “omics” platforms [11].
However, for the most part, these approaches did not
distinguish between targets that are directly involved in the
cancer pathology from those that are merely bystanders with
no functional contribution to tumourogenesis. All of these
candidate targets, obviously then, require extensive character-
isation and validation to define their relevant functional role, if
any, in cancer. It is imperative that a greater emphasis is placed
upon targets that are functionally relevant to cancer develop-
ment and progression. The significant contribution of pheno-
typic screening is well recognised in first in-class small mol-
ecule drug discovery [12]. The most commonly used ap-
proach to therapeutic antibody discovery has been to gen-
erate antibodies that are specifically directed at pre-defined,
well-characterised cell surface proteins or newly described
proteins that are less well characterised, with respect to
cancer. Early antibody candidates are generally identified
using traditional hybridoma technology developed by
Kohler and Milstein or phage display platforms which are
adapted easily for high-throughput antibody generation
[13]. Therapeutic antibody discovery is now also starting
to focus on MAb targets that are functionally relevant to the
cancer disease process, with “function first” discovery or
“phenotypic antibody screening” approaches being de-
scribed for identification of candidate MAbs that are func-
tionally involved in cancer tumourogenesis [14–16].
Our laboratory previously isolated isogenic populations of
the PDAC cell line, Mia PaCa-2 clone 3, which displays high
levels of invasion in vitro, and Mia PaCa-2 clone 8, which is
poorly invasive in vitro [17]. The use of isogenic cell lines
with different phenotypes with respect to metastasis is a very
useful model to aid in the identification of potential cancer
targets. In this study, we have used a functional MAb screen-
ing approach (based on ability to inhibit tumour invasion
in vitro) to generate functional anti-invasive MAbs using the
Mia PaCa-2 clone 3 cell line as an immunogen, in order to
identify potential targets with a direct role in cancer invasion.
Immunoprecipitation followed by liquid chromatography-
tandem mass spectrometry (LC-MS-MS) analyses was used
for target identification of the selected anti-invasive antibody.
Materials and methods
Cell lines
The triple-negative breast carcinoma (TNBC), MDA-MB-
231, HER-2 positive breast, SKBR-3, large cell lung NCI-
H1229 and the HCT-116 colon carcinoma cell lines were
obtained from the American Tissue Culture Collection
(ATCC), Rockville, MD, USA. The SNB-19 glioma cell line
was obtained from the German Collection of Microorganisms
and Cell Cultures. The Mia PaCa-2 clone 3 pancreatic cancer
cell line and the DLKP-M squamous lung carcinoma cell line
were established in our own laboratory [17, 18].
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Hybridoma generation
The immunogen chosen for the MAb generation was Mia
PaCa-2 clone 3, an invasive clonal variant of the pancreatic
cell line Mia PaCa-2 [17]. Prior to immunisations, a non-
enzymatic cell dissociation buffer was used to remove cells
from flasks (2×106 cells (50-μl volume)) following which
cells were washed and re-suspended in phosphate-buffered
saline (PBS) plus an equal volume of lipopeptide adjuvant,
Pam3Cys-SKKKK (EMC microcollections, Germany;
L2000). Each mouse received a primary immunisation admin-
istered by an intraperitoneal injection, followed by four boost-
er immunisations administered at three weekly intervals.
Three days prior to cell fusion, mice received one final
immunisation. Cell fusion of the immunised spleen B-cells
with SP/2/O-Ag myeloma cells was carried out using a mod-
ification of the fusion protocol outlined by Kohler and
Milstein [13]. Fused cells were plated out in 48-well plates
and incubated undisturbed for 10–12 days in a humidified
chamber at 37 °C/5% CO2. Immunisations were carried out at
the Royal College of Surgeons (RCSI) Biomedical Research
Facility, Beaumont Hospital, Dublin 9, Ireland; all
immunisation protocols were licensed by the Department of
Health and Children, Ireland.
Screening of hybridomas
Hybridomas were allowed to form large colonies and grow for
at least 10 days undisturbed before supernatant was removed
to screen for specific antibody production. Hybridoma super-
natants were screened directly for their ability to inhibit cell
invasion in Mia PaCa-2 clone 3 cells and for their ability to
show membrane immunoreactivity on unfixed Mia PaCa-2
clone 3 cells.
Immunofluorescence studies
Cells were suspended to a concentration of 2×106 cells/ml,
added to 10-well 7-mm microscope slides (Thermo Fisher
Scientific), and incubated overnight at 37 °C. Excess super-
natant was removed, and the microscope slides were rinsed
gently with PBS. Hybridoma supernatants were added to each
well (PBS was added to one well as a negative control). For
fixed cell immunofluorescence studies, cells were fixed in ice-
cold acetone for 2 min, followed by air-drying for 15min prior
to application of antibody 7B7. All slides were incubated
overnight at 4 °C. Primary antibodies were removed by gently
washing three times in PBS. A volume of 30 μl of secondary
antibody, fluorescein isothiocyanate (FITC)-linked rabbit anti-
mouse Ig (Dako, F0261), diluted 1/40, was added to each
well, followed by a 30-min incubation at room temperature.
Secondary antibody was removed by gently washing three
times in PBS. Each slide was mounted using VECTASHIELD
mounting medium (Vector, H-100), coverslipped and viewed
using a Nikon phase contrast microscope fitted with an FITC
filter.
96-well invasion assays
This screening assay was adapted from the standard Boyden
chamber transwell assay described previously [19], which is a
modification of the method of Albini et al. [20]. Briefly, using
Millipore 96-well invasion plates (Millipore, MAMIC8S10),
50 μl of Matrigel (1 mg/ml) (BD Biosciences, 354234) was
dispensed into each insert; the plate was incubated overnight
at 4 °C, followed by the removal of any excess Matrigel. Cells
were harvested at a concentration of 2.5×104 cells/ml in
media, and 50 μl was added to each insert, along with an
equal volume of antibody or control hybridoma medium (no
antibody). Avolume of 150 μl media was added to each insert
well. Cells were incubated at 37 °C for 48 h. Following this,
the inserts were washed with PBS to remove any cells, while
the outside of the insert was stained with 0.25% crystal violet.
Stained inserts were viewed using a Nikon inverted micro-
scope and scored as having either decreased levels of invasion
or no effect on invasion relative to control hybridoma medium
inserts (no hybridoma supernatant, representing 100 % inva-
sion). Those supernatants showing a decrease in invasionwere
re-screened using this same method.
24-well invasion assays
For 24-well invasion assays, Costar 24-well plates (Costar,
3524), containing 8.0 μm pore-sized inserts (BD Biosciences,
353097), were used. A volume of 100 μl of Matrigel was
dispensed into each insert, a cell suspension of 1×106 cells/ml
was used, and 100 μl of antibody or control hybridoma
medium (no antibody) was added to each insert; 500 μl media
were added to each insert well. Cells were incubated at 37 °C
for either 24 or 48 h, depending on the cell line used. The total
number of invading cells was determined by counting the
number of cells per field in 10 random fields at×200 magni-
fication. The average number of cells per field was then
multiplied by a factor of 140 as described previously [19].
Motility assays
Motility assays were carried out in an identical manner to 24-
well invasion assays, as described above, with the exception
that the inserts were not coated in Matrigel.
Proliferation assays
Cells were harvested at a concentration of 2×104 cells/ml in
media. Volumes of 100 μl/well of these cell suspensions were
added to a 96-well plate (Costar, 3596) using a multichannel
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pipette. Plates were gently agitated to ensure an even disper-
sion of cells over a given plate. Cells were incubated at 37 °C
in 5 % CO2 overnight. Following this, 100 μl of antibody was
added to each well. Control wells had 100 μl hybridoma
media added to the cell suspension. Plates were gently agitat-
ed, as described above, and incubated at 37 °C in 5 % CO2 for
6/7 days, until the control wells have reached 80–90 %
confluency. Assessment of cell survival in the presence of
the antibodies relative to control (no MAb—hybridoma con-
trol medium only) was determined by acid phosphatase assay
as previously described [21].
Adhesion assays
Adhesion assays were performed as described previously
[19]. A volume of 250 μl of extracellular matrix (ECM)
proteins was placed into each well of 24-well plates and
incubated overnight at 4 °C. Excess solution was removed
from the wells, followed by washing two times with sterile
PBS. To reduce non-specific binding, 0.5 ml of sterile 0.1 %
BSA/PBS solution was dispensed into each well. The plates
were incubated at 37 °C for 20 min and then rinsed twice
again with sterile PBS. Cells were harvested and re-suspended
in media at a concentration of 2.5×104 cells/ml. Aliquots of
1 ml of cells were plated onto 24-well plates, in triplicate, and
incubated for 60 min. The medium was then removed from
the wells and rinsed gently with sterile PBS. The cell number
attached was assessed using the acid phosphatase assay.
Zymography
DLKP-M cells were treated with MAb 7B7 (50 μg/ml) or
control hybridoma (no MAb) for 24 h and subsequently
transferred into serum-free medium for the collection of con-
ditioned medium for zymographic analysis (over 72 h).
Conditioned medium was concentrated 20× using an
Amicon Ultra Centrifugal Filter device (5 k MW cut-off)
and loaded onto Novex gelatin (Invitrogen EC6175) and
casein (Invitrogen EC6405) gels using a 2× non-reducing
sample buffer (Novex), renatured in zymogram renaturing
buffer and developed in zymogram developing buffer
(Invitrogen). Gels were stained with Brilliant blue G
Colloidal Coomassie (Sigma, B2025); zones of gelatinolytic/
casein activity were detected as clear bands against a blue
background.
Isotype analysis
Isotyping of MAb 7B7 was carried out using the Isostrip
Monoclonal Antibody Isotyping kit (Roche Diagnostics
Gmbh, 1493027).
Immunoprecipitation
Prior to immunoprecipitation, MAb 7B7 was purified using the
Pierce NAb Spin Purification Kit (Pierce, 20530) and dialyzed
using a Pierce Slide-A-Lyzer MINI Dialysis Unit (Pierce,
69576). Cells were grown to 80–90 % confluency, removed
from flasks, pelleted and washed three times in PBS.Whole cell
extracts were prepared by re-suspending cells in 1.5 ml of
radioimmunoprecipitation assay (RIPA) lysis buffer (Sigma,
R0278), sonicating for 5 min and centrifuging at 14,000 rpm
for 10min at 4 °C. The 7B7 antigen(s) were immunoprecipitated
from these samples using the Direct IP Kit from Pierce (45335),
as per the manufacturer’s instructions. Briefly, protein-L-
purified MAb 7B7 was covalently immobilised on aldehyde-
activated agarose beads overnight at 4 °C. The antigen (whole
cell extracts of Mia PaCa-2 clone 3 or DLKP-M cells) was then
added to immobilised antibody gel mixture together with bind-
ing buffer on a rocking platform overnight at 4 °C. The antigens
were eluted from the beaded agarose into the elution buffer (IgM
Elution Buffer, Pierce) using microcentrifuge spin cups.
Fractions were neutralised through the addition of Tris-HCl,
pH 8.8. Eluted fractions were prepared for gel electrophoresis
using NuPAGE LDS sample buffer (Invitrogen, NP007).
Following gel electrophoresis, gels were stained with Brilliant
Blue Colloidal Coomassie to visualise precipitated proteins. For
validation of mass spectrometry identifications, the gels were
probed with relevant antibodies (Ku70 and Ku80 specific anti-
bodies, Abcam, UK) for Western blot analysis.
Protein identification using LC-MS-MS
LC-MS/MS was performed on an UltiMate 3000 Nano-LC
system (Dionex), interfaced to an LTQ Orbitrap XL (Thermo
Fisher Scientific). Preparation of samples was based on the
method described by Shevehenko et al. [22]. Briefly, protein
bands were excised from the Coomassie-stained gel and were
destained. Samples were then dehydrated and digested, and
peptides were extracted with acetonitrile/0.1 % formic acid. A
5 μl aliquot of sample was loaded onto a trapping column, and
the peptides were eluted into a C18 PepMap100 nanocolumn.
Peptides were then separated using mobile phase gradient.
LC-MS/MS data were acquired in data-dependent acquisition
(DDA) mode controlled by Xcalibur 2.0.7 software (Thermo
Fisher Scientific).
Bioinformatic profiling of identified proteins
Database searches were performed using TurboSEQUEST
software (Bioworks Browser version 3.3.1) (Thermo Fisher
Scientific) using the human subset from the SWISS-PROT
database. The following filters were applied: for charge state
1, xcorr>1.5; for charge state 2, xcorr>2.5; and for charge
state 3, xcorr>3.5.
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RNA interference-mediated knockdown of Ku70 and Ku80
Two pre-designed small interfering RNAs (siRNAs, Ambion)
were chosen that target Ku70 andKu80, respectively (Ku70—
Ambion s14952 and s14953; Ku80—Ambion s5455 and
s52594), and transiently transfected into cells. Each set of
siRNA transfections carried out was accompanied with a
control (non-transfected) and a scrambled (SCR) transfection
(Ambion, 4390843). Solutions of siRNA at a final concentra-
tion of 30 nm were prepared in Opti-MEM (Invitrogen). The
siRNA experiments were set up using 2-μl NeoFX (Ambion,
AM4511), to transfect 30 nm siRNA at a cell density of 3×
105 ml in a six-well plate. Transfection medium was removed
after 24 h and replaced with fresh growth medium. A kinesin-
specific siRNA (Ambion) was used as a positive control in all
knockdown experiments to assess the efficiency of transfec-
tions. The transfected cells were collected at 72 and 96 h for
immunoblotting and assayed for changes in invasion capacity
at 24 or 48 h using the in vitro invasion assay, as described
above.
Immunoblotting
Whole cell lysates were extracted using RIPA buffer (Sigma)
containing protease inhibitor cocktail (Roche) and centrifuged
for 15 min at 16,000g at 4 °C. Protein concentrations were
determined using the BCA protein assay kit (Pierce) according
to the manufacturer’s instructions. Concentrations of 15–
30 μg of protein (whole cell extracts or immunoprecipitated
proteins) were separated using 4–12 % gradient gels
(Invitrogen) under reducing conditions. Proteins were trans-
ferred to PVDF membranes (Roche Diagnostic GmbH). The
membranes were blocked for 2 h at room temperature with
Starting BlockTM Blocking Buffer (Pierce). The membranes
were probed with MAb 7B7 supernatants, anti-Ku70 and anti-
Ku80 antibodies (Abcam, UK), β-actin or α-tubulin (T5168,
A5441, Sigma). The membranes were washed three times for
5 min with 1× Tris-buffered saline (TBS)/Tween-20 (0.5 %v/
v) and incubated with an anti-mouse HRP-conjugated second-
ary antibody (Dako) for 1 h at room temperature and washing
step repeated. Detection was performed with ECL reagents
and Amersham HyperfilmTM chemiluminescence film (GE
Healthcare).
Immunohistochemistry
A commercially available pancreatic cancer tissue microarray
(TMA) (PA1001, US BioMax), comprising of duplicate tissue
cores from 40 pancreatic cancers (including 37 pancreatic
ductal adenocarcinoma (PDAC) tumours) and 6 adjacent
non-cancer tissues, was stained for Ku70/Ku80 expression
using an anti-Ku70/Ku80 polyclonal antibody suitable for
immunohistochemistry (IHC) (Abcam, UK). Staining was
performed using an automated IHC staining apparatus
(Autostainer, Dako) according to the manufacturer’s guide-
lines. Briefly, following deparaffinisation and rehydration, the
slides were subjected to an antigen retrieval step consisting of
20-min incubation in pH 6.0 buffer (Target Retrieval, Dako).
The slides were counterstained with haematoxylin,
dehydrated in graded alcohols and glass-mounted (DPX,
Sigma). Negative control (primary antibody omitted, replaced
by TBS) and positive control (tonsil) slides were processed at
the same time. TMA cores were scored according to the
intensity of the Ku70/Ku80 immunoreactivity observed
(weak, moderate, and strong).
Quantification of MAb 7B7
MAb 7B7 was quantified using the mouse IgM ELISA quan-
tification from Bethyl Laboratories, USA (E90-101).
Statistical analysis
All data are presented as mean ± standard deviation (SD).
Analysis of the difference of comparisons, scrambled control
siRNA versus siRNA-treated mean invasion and motility
counts, adherence absorbance, and percentage survival calcu-
lated was performed using the Student’s t test (two-tailed,
unpaired with equal variance). A p value of ≤0.05, ≤0.01,
and ≤0.005 was deemed statistically significant. Statistical
analysis was performed using Microsoft Excel. All experi-
ments were repeated a minimum of three times, with the
exception of initial hybridoma invasion screening assays and
IHC analysis of Ku70/Ku80.
Results
Isolation of anti-invasive MAbs
Since trypsin may lead to the loss of cell surface antigens, a
non-enzymatic cell disassociation buffer (Sigma, C5914) was
used to remove cells from flasks prior to preparation of im-
munogen and for all screening assays for antibody character-
isation studies. Following fusion, 335 hybridoma supernatants
(77.5 % fusion efficiency) were screened using a 96-well
Boyden chamber invasion assay platform for their ability to
block invasion in Mia PaCa-2 clone 3 cells. Selected hybrid-
oma supernatants were re-screened twice (duplicate samples)
using the 96-well invasion Boyden chamber assay method.
Seven supernatants, 8B3, 1E5, 7C3, 7B7, 9D6, 5B1 and 6E2,
were selected on the basis of a decrease in invasion observed
in relation to invasion observed on controls (hybridoma con-
trol medium). These seven hybridomas were then expanded
for further characterisation. Supernatants (triplicate samples)
were re-screened by both 96-well and 24-well invasion assays.
Tumor Biol. (2014) 35:6983–6997 6987
Hybridoma Medium Control MAb 7B7 50 g/ml MAb 7B7 25 g/ml
0
1000
2000
3000
4000
5000
Hybridoma Media
Control
MAb 7B7 50μg/ml MAb 7B7 25μg/mlT
ot
al
 N
o.
 o
f I
nv
ad
in
g 
Ce
lls
*
*
c
a
Hybridoma Medium Control MAb 7B7 50 g/ml MAb 7B7 25 g/ml
0
1000
2000
3000
4000
5000
6000
Hybridoma Media
Control
MAb 7B7 50μg/ml MAb 7B7 25μg/ml
To
ta
l N
o.
 o
f I
nv
ad
in
g 
Ce
lls
**
b
d
6988 Tumor Biol. (2014) 35:6983–6997
Hybridomas 7B7 and 6E2 were selected based on their
ability to inhibit invasion. In parallel, hybridoma superna-
tants were screened for membrane fluorescence immunore-
activity using an FITC-labelled secondary antibody, on
unfixed Mia PaCa-2 clone 3 cells. Twenty-two supernatants
(from a total of 335 screened) showed strong immunoreac-
tivity on Mia Paca-2 clone 3 cells. Hybridomas 8F4, 3E2,
5B5, 1E5, 6D6 and 7B7 showed strong immunoreactivity;
8F4 and 7B7 showed more intense staining in Mia PaCa-2
clone 3 cells compared with the poorly invasive Mia PaCa-
2 clone 8 cells. Selected antibodies 7B7 and 6E2 were cloned
by limiting dilution and re-screened (duplicate samples) using
both the 24-well and the 96-well invasion assay methods. The
7B7 clone G52 was selected for further study as it showed the
strongest anti-invasive effects in Mia PaCa-2 clone 3 cells and
showed strong cell surface expression on these cells (Figs. 1
and 2) (note that 7B7 G52 is referred to, throughout this
manuscript as 7B7, its parental name).
Isotyping of MAb 7B7
Using a commercial isotyping kit, the isotype of antibody 7B7
was determined to be an IgM (data not shown).
MAb 7B7 impedes the invasive potential of aggressive cancer
cells in vitro
In order to ascertain if antibody 7B7 could also impede
invasion in other aggressive cancer cell types, we also inves-
tigated its anti-invasive effects in glioma, lung, colon and
breast cancer cell lines. Antibody 7B7 blocked the ability of
DLKP-M squamous lung carcinoma cells (mean inhibition
level of 32.2 %) (Fig. 2) and H1229 large cell lung carcinoma
cells (mean inhibition level of 30.6 %) to invade through
Matrigel (Supplementary Fig. 5). The anti-invasive effects of
7B7 in the other aggressive cancer types were not as marked:
SNB-19 glioma, mean inhibition level of 27 %; HCT-116
colon adenocarcinoma, mean inhibition level of 24.2 %;
SKBR-3 HER-2 positive breast, mean inhibition level of
25.6 %; and TNBC MDA-MB-231, mean inhibition level of
23 % in the presence of identical concentrations of 7B7
(50 μg/ml) (Supplementary Figs. 5–9) (mean inhibition, fig-
ures from a minimum of three independent experiments). To
further characterise the 7B7 functional blocking antibody, its
Fig. 1 MAb 7B7 blocks cancer invasion in PDAC Mia PaCa-2 clone 3
cells and DLKP-M squamous lung cells. a The invasive potential of Mia
PaCa-2 clone 3 cells is significantly reduced in the presence of 50 μg/ml
of antibody 7B7; invasion is also reduced, to a lesser extent, in the
presence of 25 μg/ml of antibody, indicating that MAB 7B7 can
significantly reduce the invasive potential of this cell line in a dose-
responsive manner. b The invasive potential of DLKP-M cells is
significantly reduced in the presence of 50 μg/ml of antibody 7B7;
invasion is also reduced, to a lesser extent, in the presence of 25 μg/ml
of antibody, indicating that MAB 7B7 can significantly reduce the
invasive potential of this cell line in a dose-responsive manner. In both
cases, the total number of cells invading through Matrigel is shown. Data
plotted represent the mean ± standard deviation from a representative
experiment carried out in duplicate. Statistics: *p≤0.05, **p≤0.01, and
***p≤0.005 compared with hybridoma medium control (no MAb).
Student’s t test (two-tailed with equal variance, unpaired). c
Representative photomicrographs of Mia PaCa-2 clone cells invaded
through Matrigel-coated Boyden invasion chambers (8-μm pore size)
(stained with 0.25 % crystal violet (w/v) in the presence of two different
concentrations of antibody (original magnification, ×100; scale bar=
200 μm). d Representative photomicrographs of DLKPM cells invaded
through Matrigel-coated Boyden invasion chambers (8-μm pore size)
(stained with 0.25 % crystal violet (w/v) in the presence of two different
concentrations of antibody (original magnification, ×100; scale bar=
200 μm). All experiments were performed a minimum of three times,
and representative results are presented
Fig. 2 Immunofluoresence cell surface staining of antibody 7B7. Mia
PaCa-2 clone 3 (a) and Mia PaCa-2 clone 8 (b) pancreatic ductal adeno-
carcinoma cells and DLKP Mitox-BCRP 6P, drug-resistant lung squa-
mous carcinoma cells (H. Joyce, unpublished) (c) with their sensitive
parent cells, DLKPSQ (d) and stained with antibody 7B7. Membrane
7B7 immunoreactivity is observed in invasive Mia PaCa-2 clone 3 and
drug-resistant DLKP Mitox-BCRP 6P cells, Mia PaCa-2 clone 8 cells
which are poorly invasive in vitro show more cytoplasmic-like 7B7
immunoreactivity only, DLKPSQ cells show very weak 7B7 immunore-
activity. c, d Counter stained with propidium iodide. Original magnifica-
tion of all photomicrographs, ×400, scale bar=20 μm)
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ability to inhibit invasion in a dose-responsive manner was
determined in Mia PaCa-2 clone 3 cells and DLKP-M squa-
mous carcinoma cells (Fig. 1). Antibody 7B7 significantly
inhibited invasion in a dose-responsive manner in both cell
lines; representative histograms are presented in Fig. 1.
Furthermore, 7B7 was also found to inhibit motility in a
dose-responsive manner in Mia PaCa-2 clone 3 cells
(Supplementary Fig. 3); effects on motility in other aggressive
cell types were not determined, so it cannot be concluded if
antibody 7B7 is capable of blocking cancer cell motility.
MAb 7B7 recognises a membrane-associated target antigen
Immunofluorescence staining of highly invasive Mia PaCa-2
clone 3 cells and drug-resistant Mitox6p cells with 7B7 re-
vealed strong membrane reactivity on both of these cell lines
(Fig. 2); weaker immunoreactivity was observed on poorly
invasiveMia PaCa-2 clone 8 cells and DLKP-SQ, the parental
drug-sensitive clone of DLKPSQ Mitox-BCRP 6P. These
results suggested that the 7B7 antigen may possibly be asso-
ciated with an aggressive cancer phenotype, i.e. highly inva-
sive or drug-resistant cells relative to poorly invasive/drug-
sensitive cells. Taken together with 7B7s ability to impede the
invasive potential of various cancer cell types, the observed
7B7 immunoreactivity strongly suggests that this antibody
binds to its native putative target antigen on the cell surface
in these invasive cell lines.
Identification of the 7B7 target antigen
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) separation followed by Western blotting analy-
sis with antibody 7B7 revealed no potential reactive antigen
band(s), suggesting that this antibody is recognising a confor-
mational and not a linear epitope. We previously successfully
used an immunoprecipitation approach coupled with proteo-
mic analysis to identify the target antigen of antibody 5C3
[23]. As we had determined the isotype of antibody 7B7 to be
an IgM, we used a modification of our previous approach
utilising a commercially sourced immunoprecipitation kit
which involved directed immobilisation of purified antibody
to aldehyde-activated agarose beads. So in addition to elimi-
nating immunoprecipitated contaminating antibody, protein
A/G is not involved, thus its suitability for IgM immobilisa-
tion. Cell extracts from Mia PaCa-2 clone 3 cells and DLKP-
M cells were immunoprecipitated with MAb 7B7. SDS-
PAGE and MS-compatible Coomassie Blue staining revealed
two reactive bands of approximately 80 and 70 kDa, in
immunoprecipitates from both cell lines which were not pres-
ent on control mouse IgM immunoprecipitates. A representa-
tive gel is shown in Fig. 3 showing reactive bands in
immunoprecipitated Mia PaCa-2 clone 3 extracts. These two
bands were excised and subjected to mass spectrometry
identification using the SWISS-PROT database; the 70 and
80-kDa bands were identified as the ATP-dependent DNA
helicase 2 subunit 1 (Ku70) (molecular weight, 69.79 kDa)
and the 80 kDa ATP-dependent DNA helicase 2 subunit 2
(Ku80) (molecular weight, 82.65 kDa) (Table 1).
Immunoprecipitates were validated with commercial antibod-
ies directed against Ku70 and Ku80, confirming these identi-
fications (Supplementary Fig. 18).
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Fig. 3 Identification of MAb 7B7 target antigens by immunoprecipita-
tion. Cross-linked immunoprecipitation of cell lysates with 7B7MAb and
control mouse IgM separated by SDS-PAGE and stained with 0.25 %
Coomassie Blue. Lane 1 molecular weight markers, lane 2 Mia PaCa-2
clone 3 immunoprecipitated with mouse IgM, lane 3Mia PaCa-2 clone 3
immunoprecipitated with MAb 7B7. Two bands are observed; at approx-
imately 80 kDa, 70 kDa was excised and run through an LCMS/LTQ
mass spectrometer for identification. No antibody heavy and light chains
are present. Non-binding agarose beads were also used as a control (data
not shown). Experiment was performed three times, and a representative
scanned gel is shown. DLKP-M cells were also immunoprecipitated with
antibody 7B7 and resulted in the same 70 and 80-kDa reactive bands
(data not shown)
Table 1 The 7B7 target antigens identified by immunoprecipitation/LC-
MS-MS
Protein name Gene
symbol
Protein AC
number
MW (kDa)
ATP-dependent DNA
helicase 2 subunit 1
XRCC6 gi|169145199| 69.79
ATP-dependent DNA
helicase 2 subunit 2
XRCC5 gi|125731| 82.65
These proteomic identifications were validated by probing Mia PaCa-2
clone 3 and DLKP-M immunoprecipitates with commercial antibodies
specific for both the Ku70 and Ku80 subunits of the Ku heterodimer,
confirming these proteomic identifications
MW molecular weight
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RNA interference-mediated knockdown of Ku70 and Ku80
suppresses the invasive capacity of Mia PaCa-2 clone 3
and DLKP-M cells
As we had demonstrated that incubation with MAb 7B7 can
significantly inhibit tumour invasion in a dose-responsive
manner in the Mia PaCa-2 clone 3 and DLKP-M cell lines,
we then determined the effects of siRNA-mediated knock-
down on proliferation and invasion to establish if Ku70/Ku80
is functionally involved and thus has therapeutic relevance in
these two aggressive cancer types. Two independent siRNAs
were used to successfully knockdown both subunits of the Ku
heterodimer in the two cell lines. Down regulation of both
Ku70 and Ku80 significantly reduced the invasive capacity of
both cell lines to invade compared with cells transfected with
scrambled control siRNA as indicated by amarked decrease in
the number of cells invading through matrigel (Figs. 4 and 5).
Cells transfected with Ku70 and Ku80 siRNA grew at a
similar rate to scrambled control transfected cells indicating
that down regulation of Ku70/Ku80 has no effect on prolifer-
ation in these cell lines, indicating that the anti-invasive effects
of antibody 7B7 are not secondary to the effects on cell growth
(Supplementary Figs. 12 and 13). These siRNA knockdown
experiments demonstrate that Ku70 and Ku80 are required for
invasion of these aggressive PDAC and squamous lung car-
cinoma cell lines and thus are functionally involved in pan-
creatic and lung cancer invasion in vitro.
MAb 7B7 impedes the adhesion potential of Mia PaCa-2
clone 3 and DLKP-M cells
Adhesion of a tumourigenic cell to the basement membrane is
a crucial stage in the invasion process. Thus, the effect of
MAb 7B7 on the adhesive potential of Mia PaCa-2 clone 3
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Fig. 4 The siRNA-mediated interference knockdown of both Ku70 and
Ku80 reduces invasive capacity of Mia PaCa-2 clone 3 cells. a, b
Immunoblots showing effective knockdown of Ku70 (a) and Ku80 (b)
at 48-h post-transfection in Mia PaCa-2 clone 3 cells transfected with two
independent siRNAs targeting Ku70 and Ku80, respectively, relative to
scrambled control siRNA-transfected cells.α-Tubulin served as a loading
control. c, d Representative histograms showing reduced invasive capac-
ity of Mia PaCa-2 clone 3 cells in a Boyden chamber assay following
transfection with Ku70- and Ku80-targeted siRNAs. The total number of
cells invading throughMatrigel is shown. Data plotted represent the mean
± standard deviation of duplicate transwell inserts from a representative
experiment. Statistics: *p≤0.05, **p≤0.01, and ***p≤0.005 compared
with scrambled siRNA control. Student’s t test (two-tailed with equal
variance, unpaired). e, f Representative photomicrographs showing inva-
sion status of Mia PaCa-2 clone 3 cells following transfection with
siRNAs targeting Ku70 (e) and Ku80 (f), respectively. A decrease in
invasion can be observed following siRNA transfections of both Ku70
and Ku80 compared with scrambled control insert. Original magnifica-
tion, ×100; scale bar=200 μm. All experiments were performed in a
minimum of three times, and representative results are presented
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cells was assessed. In the presence of MAb 7B7, a small
decrease in the adhesion of Mia PaCa-2 clone 3 cells to
matrigel and DLKP-M cells to fibronectin was observed
(Supplementary Figs. 10 and 11).
MAb inhibits MMP activity in DLKPM cells
Following treatment of squamous lung DLKP cells with anti-
body 7B7, effects on MMP activity were determined. As
demonstrated in Fig. 6, zymographic analysis of conditioned
medium (collected over 72 h) from DLKP-M cells treated for
24 h with antibody 7B7 revealed reductions in pro and active
MMP-10 and pro-MMP-2 compared with conditioned medi-
um from cells treated with hybridoma control medium only.
These results indicated that 7B7 may be eliciting its anti-
invasive effects through reduction of MMP-2 and MMP-10
activities in DLKP-M cells.
IHC analysis of Ku70/Ku80 expression in pancreatic cancer
TMA cores were scored according to the intensity of the
Ku70/Ku80 immunoreactivity observed (weak, moderate,
and strong) (Table 2). Duplicate cores were stained in all
cases; there was complete concordance between duplicates.
Nuclear Ku70/Ku80 immunoreactivity was observed in all
cases; some cytoplasmic localised staining was also observed.
In addition, cytoplasmic staining of stromal cells was ob-
served in a number of tumours. Ku70/Ku80 immunoreactivity
was present in 40/40 tumours (37 PDAC, 2 acinar, and 1
squamous). All of the high-grade tumours studied exhibited
either moderate or strong Ku70/Ku80 immunoreactivity, sug-
gesting a possible trend of increased expression of
Ku70/Ku80 with more aggressive PDAC tumours. Weak
Ku70/Ku80 expression was also observed in 2/5 normal pan-
creatic tissues; 3/5 tissues showed intermediate immunoreac-
tivity. Representative photomicrographs are shown in Fig. 7.
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Fig. 5 siRNA-mediated interference knockdown of both Ku70 and
Ku80 reduces invasive capacity of DLKP-M cells. a, b Immunoblots
showing effective knockdown of Ku70 (a) and Ku80 (b) at 48-h post-
transfection in DLKP-M cells transfected with two independent siRNAs
targeting Ku70 and Ku80, respectively, relative to scramble control
siRNA-transfected cells. α-Tubulin served as a loading control. c, d
Representative histograms showing reduced invasive capacity of
DLKP-M cells in a Boyden chamber assay following transfection with
Ku70 and Ku80 siRNAs. The total number of cells invading through
matrigel is shown. Data plotted represent the mean ± standard deviation
of duplicate transwell inserts from a representative experiment. Statistics:
*p≤0.05, **p≤0.01, and ***p≤0.005 compared with scrambled siRNA
control. Student’s t test (two-tailed with equal variance, unpaired). e, f
Representative photomicrographs showing invasion status of DLKP-M
cells following transfection siRNAs targeting Ku70 (e) and Ku80 (f),
respectively. A decrease in invasion can be observed following siRNA
transfection of both Ku70 and Ku80 compared with scrambled control
insert. Original magnification, ×100; scale bar=200 μm). All experi-
ments were performed in a minimum of three times, and representative
results are presented
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We were not able to establish if membrane Ku70/Ku80 ex-
pression is present in PDAC, as this commercial antibody has
not been demonstrated to be specific for Ku70/Ku80 mem-
brane expression.
Discussion
Despite the considerable success of MAbs in cancer therapy,
there is still an unmet need for novel antibody therapeutics in
oncology. Metastasis remains a huge therapeutic challenge,
and a number of aggressive cancers currently lack well-
defined therapeutic targets. The key challenge for antibody
discovery for these unmet cancers is the continued identifica-
tion of novel targets that are suitable for therapeutic antibody
or ADC targeting. Therapeutic antibody target discovery can
broadly be classified into two main approaches: antibody
targeting of proteins with established, validated roles in cancer
and antibody development without prior knowledge of the
target which is based on functional screening.
Here, we report the isolation and characterisation of an anti-
invasive blocking antibody which was identified using such a
“functional screening” or function first hybridoma screening
approach. Such phenotypic-based antibody screening ap-
proaches are increasingly been described for antibody discov-
ery [24]. Our strategy involved the generation and selection of
functional anti-invasive MAbs directed against theMia PaCa-2
clone 3 cell line, with the overall objective of identifying cell
surface protein targets with a direct role in cancer invasion that
may be tractable to antibody/ADC therapy. This isogenic cell
line which was previously isolated in this laboratory displays
the characteristics of an aggressive cancer, with decreased
adhesion facilitating increased invasion and motility coupled
with an ability to survive in anchorage-independent conditions
[19]. Furthermore, by immunising with cancer cells expressing
functionally important antigens in their native cell surface
configuration, it was more likely that we would isolate highly
tumour-selective antibodies. Following fusion, hybridomas
were screened based on their ability to inhibit invasion in their
target cell line, Mia PaCa-2 clone 3. In parallel, hybridoma
supernatants were also screened by immunofluorescence stain-
ing on unfixedMia PaCa-2 clone 3 cells. Cell surface receptors
are key targets for antibody-based therapeutics and account for
over two thirds of current drug targets. The selected antibody
7B7 was chosen for further study, based on its ability to
significantly impede invasion in Mia PaCa-2 clone 3 cells
and its strong membrane immunoreactivity in Mia PaCa-2
clone 3 cells with reduced staining in poorly invasive clone 8
cells. DLKP SQ Mitox6p cells, a drug-resistant clone also
exhibited strong 7B7 immunoreactivity compared with its
drug-sensitive parent (H. Joyce, unpublished). So, it appeared
that the 7B7 target antigen may possibly be more highly
expressed in cell lines that are representative of a more aggres-
sive phenotype, i.e. highly invasive and/or chemoresistant.
We further demonstrated that antibody 7B7 could reduce
cancer invasion in a panel of cell lines representing other
aggressive tumour types (lung, glioma, colon, and breast).
Its anti-invasive effects, however, were not as strong as that
observed inMia PaCa-2 clone 3. The observed variation in the
extent of inhibition may reflect varying expression of the 7B7
target antigen in these cell lines, or it may suggest that our
antibody is more selective for Mia PaCa-2 clone 3 PDAC
cells. As the most striking anti-invasive effects were observed
in pancreatic and lung cell lines, we then demonstrated that
MAb 7B7 can significantly reduce invasion in a dose-
dependent manner in both Mia PaCa-2 clone 3 and DLKP-
M cells. Tumour invasion involves both the formation and the
loss of adhesive contacts of tumour cells with the extracellular
matrix. A small reduction in adhesion of Mia PaCa-2 clone 3
cells to ECM protein, fibronectin, and in adhesion of DLKP-
M cells to Matrigel in the presence of MAb 7B7 was also
observed; this inhibitory effect on adhesion may be contribut-
ing to the significant decreases in the invasive potential ob-
served in these aggressive cancer cells lines with MAb 7B7.
In addition to identifying a functional MAb with
invasion-blocking activity, our study also aimed to reveal
its target antigen. No signals could be detected when
Western blotting was performed with antibody 7B7, sug-
gesting that 7B7 is recognising a conformational and not a
linear epitope. The anti-invasive effects of antibody 7B7
and cell surface immunoreactivity observed in invasive
cancer cells indicate that this antibody is recognising a
native target antigen on the membrane of these cells.
Using an immunoprecipitation cross-lined method, mass
spectrometry analysis using LC-MS-MS identified the
immunoprecipitated 70 and 80 kDa bands as the ATP-
dependent DNA helicase 2 subunit 1 (Ku70) and the
80 kDa ATP-dependent DNA helicase 2 subunit 2 (Ku80)
(Table 1). The antibody immunoprecipitates were validated
with commercial antibodies directed against the Ku70 and
Ku80 subunits, confirming the proteomic identifications
(Supplementary data). Ku is a heterodimeric protein com-
posed of two subunits, Ku70 and Ku80; it was originally
identified as an auto-antigen recognised by the sera of
patients with autoimmune disease [25]. It is normally found
in the nucleus where it plays a key role in non-homologous
end joining (NHEJ), a major pathway in DSB repairs in
humans [26]. Ku70/Ku80 is a key mediator in NHEJ and
has been implicated in the radiosensitivity of a number of
cancer types including the bladder, lung, breast, glioma,
prostate, head and neck and cervix [27–34]. Ku has also
been reported to be involved in cisplatin chemoresistance of
some aggressive cancers such as lung adenocarcinoma,
ovarian and leukaemic cells [30, 34].
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Functional antibody-blocking experiments with MAb 7B7
directed against Ku70/Ku80 had demonstrated that incubation
of Mia PaCa-2 clone 3 and DLKP-M cells with this anti-
invasive antibody strongly suppressed invasion in a dose-
dependent manner in both cell lines. We then demonstrated
that, for the first time, siRNA duplexes specific for both Ku70
and Ku80 could substantially reduce the invasive capacity of
PDAC (Mia PaCa-2 clone 3) and lung squamous cancer cells
(DLKP-M). These RNA interference-mediated knockdown
results further strengthen our antibody-blocking results, indi-
cating the functional involvement of Ku70/Ku80 in pancreatic
and lung cancer invasion. The Ku heterodimer has been found
to be expressed on the cell surface of various cancer cell lines
(e.g. neuroblastoma, breast, cervix, and multiple myeloma)
[26]. Ku80 has been found to associate with latent and active
MMP-9 on the cell surface of highly invasive haemapoietic
cells [35]. MAb 7B7 showed strong membrane reactivity on
invasive Mia PaCa-2 clone 3 cells and on drug-resistant
Mitox6p cells. Together with the anti-invasive effects of
MAb 7B7, these results strongly suggest that our antibody
shows specificity for membrane-associated Ku70/Ku80. A
number of antibodies have been developed against
Ku70/Ku80; only one of these, the INCA-X antibody, has
been demonstrated to showmembrane-associated Ku70/Ku80
expression in human cancer tissue, glioma [36]. This group
also demonstrated, using their antibody, that Ku70/Ku80 is
internalised into pancreatic carcinoma cells, suggesting that it
has potential therapeutic value [37]. To our best knowledge,
the involvement of Ku70/Ku80 in invasion of this aggressive
cancer type or in lung cancer has not been studied to date.
Studies on the role of Ku70/Ku80 in cancer invasion/
progression are limited. Inhibition of Ku80 with either
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Fig. 6 Antibody 7B7 reduces MMP activity in squamous lung carcino-
ma DLKP-M cells. MMP activity in DLKP-M cells. a Gelatin
zymography analysis of conditioned medium collected over 72 h from
DLKP-M cells showing presence of both pro and active (lower band)
MMP-2 in DLKP-M cells. b Caesin zymography analysis of conditioned
medium collected over 72 h fromDLKP-M cells showing the presence of
both pro and active (lower band) MMP-10 in DLKP-M cells. MMP
activity in DLKP-M cells treated with antibody 7B7. c Gelatin
zymography analysis of conditioned medium collected over 72 h
following treatment of DLKP-M cells with 50 μg of MAb 7B7. A
reduction in MMP-2 activity in DLKP-M antibody-treated cells is ob-
served compared with control hybridoma medium only (no antibody). d
Caesin zymography analysis of conditioned medium collected over 72 h
following treatment with antibody 7B7. A marked reduction in MMP-10
activity (pro and active) is observed in DLKP-M cells treated with
antibody 7B7 compared with cells treated with control hybridoma medi-
um only (no antibody). Three independent experiments were performed
in all cases, and representative zymograms are shown
Table 2 Ku70/Ku80 immunoreactivity in grades 1, 2 and 3 PDAC
tumours
Grade 3 5/12 strong
7/12 moderate
Grade 2 3/12 strong
5/12 moderate
4/12 weak
Grade 1 3/13 strong
7/13 moderate
3/13 weak
Immunohistochemical analysis of Ku70/Ku80 in 37 PDAC tumours
(duplicate cores), scores from histological grade 1 (low grade), grade 2
(intermediate) and grade 3 (high grade, more aggressive) PDAC tumours,
is presented. The Ku70/Ku80 (nuclear immunoreactivity) staining inten-
sity was scored for each as weak, moderate or strong. Results presented
represent the combined score of two cores from each tumour. High-grade
tumours showed either moderate or strong immunoreactivity in all cases,
suggesting a possible association of Ku70/Ku80 expression with a more
aggressive PDAC phenotype. Representative photomicrographs are
shown in Fig. 7
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neutralising antibodies or siRNA strongly reduced TRK-
mediated breast cancer invasion cancer [38].
To investigate how 7B7 may be exerting its anti-invasive
effects, we then determined if antibody 7B7 could alter MMP
activity. Treatment of DLKP-M cells with antibody 7B7 re-
sulted in a reduction in both MMP-2 and MMP-10 activities.
Ku70/Ku80 has been shown to interact withMMP-9 in highly
invasive cancer cells; to our knowledge, interactions with
other MMPs have not been reported. So, antibody 7B7 may
possibly be eliciting its anti-invasive effects by reducing
MMP activity, at least in the cell line studied here.
It is likely that tumour progression is associated with en-
hanced NHEJ, and up regulation of Ku70/Ku80 has been
reported in a number of aggressive tumours such as lung
adenocarcinoma, breast and gastric cancers [34, 39, 40].
Conversely, it has been suggested that deficient expression
or lack of Ku70/Ku80 may result in genomic instability lead-
ing to tumourogenesis [41]. Earlier phases of melanoma pro-
gression are associated with loss of expression of Ku70/Ku80,
and the binding activity of Ku70/Ku80 was reported to be
strongly reduced at the advanced tumour stage in breast and
bladder tumours [42, 43]. There are limited investigations
focused on DNA repair proteins in pancreatic cancer. Ku70
has been implicated in the radiosensitivity of pancreatic car-
cinoma cells, has been shown to block Bax-mediated apopto-
sis and has been shown to be a secondary target for MDM2
inhibitor [44]. PDAC is highly refractory to systemic therapies
and is characterised by a high propensity for local invasion
and distant metastasis. There is an urgent need to develop new
therapeutic strategies for this neoplasm. To ascertain if altered
expression of Ku70/Ku80 is involved in tumourogenesis in
PDAC, we determined, using IHC, Ku70/Ku80 expression in
37 PDAC tumours and 6 normal pancreatic tissues. Our
characterisation studies indicated that the 7B7 epitope was
destroyed upon formalin fixation as we did not observe any
immunoreactivity on archival tissues; therefore, a commercial
Ku70/Ku80 antibody was used for IHC studies. The Ku
protein was expressed in all tumours studied, with a trend
towards possible elevated expression of Ku70/Ku80 in higher
grade, i.e. more aggressive tumours. Ku70/Ku80 immunore-
activity was also observed in stromal cells in a number of
tumours. We did observe Ku70/Ku80 expression in some of
the normal pancreatic tissues stained, albeit weaker immuno-
reactivity than that observed in the majority of the tumours.
Determination of Ku70/Ku80 immunoreactivity (and tumour
membrane specificity, if this can be demonstrated) in a larger
PDAC patient cohort with follow-up will clarify the role of
Ku70/Ku80 in PDAC progression. In terms of its application
as a potential antibody target for PDAC (or other aggressive
neoplasms), immunohistochemical expression levels in an
extended panel of normal tissues (including haemopoietic
cells) will need to be carried out.
The preliminary IHC results presented here, however, dem-
onstrate, for the first time, that Ku70/Ku80 is widely
Fig. 7 Immunohistochemical analysis of Ku70/Ku80 in (PDAC).
Ku70/Ku80 expression was studied in 37 PDAC tumours and 5 normal
pancreatic tissues using a commercial pancreatic cancer TMA (US
Biomax). Duplicate cores from each patient were stained, and
Ku70/Ku80 immunoreactivity was scored according to the staining in-
tensity observed (weak, moderate, and strong; Table 2). Representative
photomicrographs are shown, a a low-grade PDAC tumour showing
weak Ku70/Ku80 immunoreactivity, while strong Ku70/Ku80-positive
staining is observed in grade 2 (b) and grade 3 tumours (d). Stromal
Ku70/Ku80 immunoreactivity can be observed in d and in a second high-
grade PDAC (c). Original magnification of photomicrographs of a, b and
d is×400 (scale bar=100 μm; c×200 (scale bar=50 μm)
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expressed in PDAC. Taken together with invasion blocking
and siRNA-mediated knockdown experiments, our study pro-
vides further evidence that targeting Ku70/Ku80 with anti-
bodies has therapeutic potential in pancreatic cancer. Our
observed anti-invasive effects in other cancer cells, while not
as striking as Mia PaCa-2 clone 3 and DLKP-M, suggest that
Ku70/Ku80 may be involved in the invasion of other aggres-
sive cancer types; further, RNA-mediated interference knock-
down studies would need to be carried out to confirm any
potential functional role for Ku70/Ku80 in these cancer types.
In summary, we have identified a cancer cell surface pro-
tein representing a potential therapeutic target through char-
acterisation of an anti-invasive MAb generated using a func-
tional hybridoma screening approach. Selection of MAbs
based on their ability to inhibit cancer invasion and
immunoprecipitation-based proteomic identification of puta-
tive target antigens has the potential to identify novel candi-
date membrane proteins for therapeutic antibody targeting or
ADC targeting. Furthermore, our approach may also comple-
ment pre-defined target discovery approaches by assigning
cancer-invasive-associated functions to known targets.
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